Clincosm LogoSign in Get a demo

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Sponsor
Alliance Foundation Trials, LLC. (Other)
Overall Status
Recruiting
CT.gov ID
NCT04062708
Collaborator
AstraZeneca (Industry)
55
Enrollment
15
Locations
1
Arm
41.8
Anticipated Duration (Months)
3.7
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a single arm, phase II trial of combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles for patients with potentially resectable stage IIIA and IIIB (T1-3, N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study is to increase N2 nodal clearance (N2NC) to 50% or greater for combined platinum doublet chemotherapy with durvalumab induction therapy from historical rate of 30% for platinum doublet chemotherapy alone in patients with potentially resectable stage IIIA/B (N2) NSCLC.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

In the preoperative period, patients who have undergone adequate mediastinal evaluation and are considered operable will be treated with durvalumab 1125 mg IV every 3 weeks (Q3W) in combination with platinum doublet chemotherapy (cisplatin with pemetrexed or docetaxel, depending upon histology).

Patients will undergo postoperative radiation (54Gy) within 4-10 weeks after surgery (unless single station N2 at registration with resultant ypT0N0 after neoadjuvant therapy).

One to 6 weeks after completion of radiation, patients will receive adjuvant durvalumab 1500 mg IV every 4weeks (Q4W) for 1 year.

Patients who do not have surgery due to refusal, physician decision, or local and distant progression will have to discontinue study treatment.

All participants will have imaging assessment prior to surgery after Cycle 2 (Week 6) and after Cycle 4 (Weeks 13 15). Patients will undergo potentially curable surgery as per standard of care.

Patients will undergo imaging assessment every 12 weeks after surgery for 2 years, then every 6 months for 3 years.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
55 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Actual Study Start Date :
Mar 10, 2021
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

Combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles.

Drug: Durvalumab
Preoperative Treatment: Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles Adjuvant Therapy: • 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles.
Other Names:
  • Imfinzi

    • Procedure: Surgery
    Patients will be re-evaluated following preoperative treatment to assess if patient is still medically fit to withstand surgery. Eligible patients will then undergo lobectomy, bilobectomy, sleeve lobectomy or other extended resection, or a pneumonectomy will be performed at the discretion of the attending thoracic surgeon.

    Radiation: Radiotherapy
    4-10 weeks after surgery, patients will receive 54 Gy of radiotherapy with single daily fractions.

    Outcome Measures

    Primary Outcome Measures

    1. N2 nodal clearance (N2NC) [5 years]

      To increase N2 nodal clearance (N2NC) to 50% or greater for combined platinum doublet chemotherapy with durvalumab induction from an historical rate of 30% for platinum doublet chemotherapy alone in patients with potentially resectable stage IIIA/B (N2) NSCLC.

    Secondary Outcome Measures

    1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [5 years]

      To evaluate the safety and tolerability of neoadjuvant platinum doublet chemotherapy and durvalumab followed by surgery followed by adjuvant radiation and durvalumab.

    2. Radiographic response rate [5 years]

      To assess the radiographic response rate of neoadjuvant platinum doublet chemotherapy and durvalumab.

    3. Rate of major pathologic response and pathologic complete response [16 weeks]

      To evaluate the rate of major pathologic response and pathologic complete response in the resected primary tumor and lymph nodes following neoadjuvant combination therapy.

    4. Evaluate event free survival (EFS) [5 years]

      EFS evaluated from the time of registration to one of the following events, whichever comes first: a) radiographic disease progression, b) local progression as defined by lymph node progression precluding surgery, c) inability to resect the tumor, d) local or distant recurrence, e) death due to any cause.

    5. Overall survival rate [5 years]

      To evaluate overall survival rate from the time of registration

    6. Rate of complete resection. [16 weeks]

      To assess the rate of complete resection.

    7. Post-operative complications [Within 30 days of surgery]

      To assess post-operative complications

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Operability Criteria:

    1. ECOG Performance Status 0-1.

    2. Absence of major associated comorbidities that increase the surgery risk to an unacceptable level.

    3. Pulmonary function capacity capable of tolerating the proposed lung resection. FEV1 at least 2 L. If less than 2 L, the predicted postoperative forced expiratory volume in 1 second (FEV1) must be >0.8 L or be >35% of the predicted value. Postoperative predicted DLCO ≥35% is required.

    Inclusion Criteria:

    1. Patients who are at least 18 years of age.

    2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

    3. Life expectancy of at least 12 weeks.

    4. Patients with potentially resectable IIIA/B (T1-3, N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification) who are candidates for surgery with intent of R0 resection. Invasive T3 disease (eg, phrenic nerve, pericardium, chest wall other than Pancoast superior sulcus) may be included if the surgeon and study team deem it to be resectable. T4 disease per AJCC 8th edition staging system is excluded given the lack of benefit of surgery in T4N2.

    5. Patients must be evaluated by a thoracic surgeon within 4 weeks of registration.

    6. Operability is defined as having adequate pulmonary, cardiac, renal, nutritional, musculoskeletal, neurologic, and cognitive capacity to undergo major pulmonary resection with acceptable morbidity and mortality.

    7. N2 nodes must be discrete (ie, not invading surrounding structures) and less than 3 cm in maximum diameter.

    8. Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

    9. Pathologically proven N2 disease within 4 weeks of registration. PET/CT positivity in the ipsilateral mediastinal nodes will not be sufficient to establish N2 nodal status. Mediastinal lymph node sampling biopsy is required pre-operatively by at least one of the following:

    • Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA);

    • Mediastinoscopy;

    • Mediastinotomy (Chamberlain procedure);

    • Endoscopic ultrasound guided node aspiration (EUS);

    • Video-assisted thoracoscopy; OR

    • Fine needle aspiration by image guidance.

    • Endobronchial ultrasound (EBUS) or mediastinoscopy or other tissue sampling (at least 2 stations must be biopsied, with at least one station positive for N2 disease). If there are any mediastinal nodes suspicious by CT (>1.5 cm) or PET in N3 stations, they must be biopsied. If biopsy proven involvement in an N3 station, the patient is excluded.

    1. Mediastinal nodal biopsy or aspiration can only be omitted in the special circumstance in which ALL of the following are true:

    • The tumor is left sided;

    • The only mediastinal nodal involvement is a node visible in the AP (level 5) region on CT scan;

    • Distinct primary tumor separate from the nodes; AND

    • Biopsy proven non-small cell histology from the primary tumor.

    1. No prior history of thoracic radiation.

    2. Organ and marrow function definitions (example below)

    • leukocytes ≥3,000/mcL

    • absolute neutrophil count ≥1,500/mcL

    • platelets ≥100,000/mcL

    • Hemoglobin >9.0 g/dL

    • total bilirubin within normal institutional limits

    • AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal

    • creatinine within normal institutional limits OR

    • creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.

    1. Patients are capable of giving informed consent and/or have an acceptable surrogate capable of giving consent on the subject's behalf.

    2. Nonpregnant and non-nursing. The effect of durvalumab on the fetus is unknown.

    3. Women of childbearing potential (WOCBP) must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 3 months after the last dose of study medication. Patients of childbearing potential are those who have not been surgically sterilized or have not been free of menses >1 year.

    4. Evidence of postmenopausal status or negative urinary or serum pregnancy test for female premenopausal patients. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    • Women <50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).

    • Women ≥50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).

    1. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

    2. Male patients must agree to use an adequate method of contraception starting with the first dose of study therapy through 12 weeks after the last dose of study therapy.

    Exclusion Criteria:

    1. Any prior treatment for NSCLC.

    2. Prior thoracic radiation.

    3. Patients with ≥Grade 2 peripheral neuropathy.

    4. Any active or history of autoimmune disease (including any history of inflammatory bowel disease) or history of a syndrome that required systemic steroids or immunosuppressive medications, except for patients with vitiligo or resolved childhood asthma/atopy.

    5. Patients requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses <10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

    6. Patients with previous malignancies (except nonmelanoma skin cancers, in situ bladder, gastric, breast, colon or cervical cancers/dysplasia) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.

    7. History of solid organ transplant.

    8. N3 nodal disease.

    9. Mixed small cell/NSCLC will be excluded.

    10. Pregnant or breastfeeding.

    11. History of allogenic organ transplantation.

    12. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], active diverticulitis with the exception of diverticulosis, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia.

    • Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement.

    • Any chronic skin condition that does not require systemic therapy.

    • Patients without active disease in the last 5 years may be included but only after consultation with the study physician.

    • Patients with celiac disease controlled by diet alone.

    1. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.

    2. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UCSD Moores Cancer Center San Diego California United States 92037
    2 NorthWestern University Chicago Illinois United States 60611
    3 University of Chicago Medical Center Chicago Illinois United States 60637
    4 Massachusetts General Hospital Boston Massachusetts United States 02114
    5 Brigham and Women's Hospital Boston Massachusetts United States 02115
    6 Lowell General Hospital Lowell Massachusetts United States 01854
    7 St. Joseph Mercy Hospital Ypsilanti Michigan United States 48197
    8 Mayo Clinic Rochester Rochester Minnesota United States 55901
    9 Dartmouth Hitchcock Medical Center Manchester New Hampshire United States 03103
    10 Roswell Park Comprehensive Cancer Center Buffalo New York United States 14263
    11 SUNY Upstate Medical University Syracuse New York United States 13210
    12 University of Oklahoma Health Sciences Center Oklahoma City Oklahoma United States 73104
    13 Baptist Cancer Center Memphis Tennessee United States 38120
    14 University of Texas MD Anderson Cancer Center Houston Texas United States 77030
    15 University of Virginia Health System Charlottesville Virginia United States 22908

    Sponsors and Collaborators

    • Alliance Foundation Trials, LLC.
    • AstraZeneca

    Investigators

    • Principal Investigator: Monica Bertagnolli, MD, Alliance Foundation Trials, LLC.
    • Study Chair: Linda Martin, MD, MPH, University of Virginia
    • Study Chair: Jyoti Patel, MD, University of Chicago
    • Study Chair: James Urbanic, MD, University of California, San Diego

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Alliance Foundation Trials, LLC.
    ClinicalTrials.gov Identifier:
    NCT04062708
    Other Study ID Numbers:
    • AFT-46
    First Posted:
    Aug 20, 2019
    Last Update Posted:
    Dec 8, 2021
    Last Verified:
    Jun 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Alliance Foundation Trials, LLC.
    Stage IIIA/IIIB (T1-3,N2) Non-Small Cell Lung Cancer (NSCLC)
    Additional relevant MeSH terms:
    Lung Neoplasms
    Carcinoma, Non-Small-Cell Lung
    Durvalumab

    Study Results

    No Results Posted as of Dec 8, 2021